Axol Bioscience Ltd.

iPSC technology for dry AMD disease models: ➡ Our friends at Phenocell have been working on iPSC-derived models for age-related macular degeneration (AMD), the leading cause of blindness in the elderly population that currently affects over 200 million people worldwide. ➡ AMD can be characterized as “wet” (exudative) or “dry” (non-exudative), with the dry form accounting for around 90% of all cases. Despite this, there are currently no therapies for dry AMD and so, with rates expected to increase by 44% by 2040, there is a pressing need to develop human-relevant models to unlock insights and drive new therapies Phenocell are tackling this with iPSC products and services geared towards human-relevant dry AMD models. They have performed extensive characterization and validation of the key cell type (retinal pigment epithelium, RPE) and have developed a range of assays for dry AMD research. Check out their document below - #amd #ipsc #drugscreening

We're here to help. At Axol, we've spent more than a decade at the forefront of iPSC technology, developing expertise in using iPSC-derived cells for drug discovery and research. Our straightforward workflows and simple to read protocols ensure you get the best from your cells, and we are always on hand to support you in achieving your goals. Dr Jamie Bhagwan is a Scientific Group Leader at Axol, primarily working on cardiomyocyte related R&D, and service projects, and using his expertise to guide the scientific team. Jamie is happy to share his hard-won experience of working with cardiomyocytes - here are his top tips: 1. Seeding densities - Jamie recommends using about 150,000-200,000 cells/cm², but you can optimize this to ensure cells form a full monolayer o Be aware that there may be differences in cells attachment between tissue culture treated plastic from different suppliers 2. Take care when handling cells - pipette using larger bore pipette tips if possible, and don't pipette too vigorously! 3. Jamie recommends adding 10% FBS and 10μm ROCK inhibitor to plating media o Make sure the ROCK inhibitor is in date, and be aware that it is light sensitive o (some other groups have used CloneR™2) o After 24h, change media to standard maintenance media 4. Do not try to passage cells, plate onto your final assay format Don't hesitate to contact us if you have any questions about working with axoCells™ cardiomyocytes, or you would like to use them to develop human-relevant models for drug discovery and researchoperations@axolbio.com Click here to watch the Tech Clinic on Human iPSC-Derived Cardiomyocytes: https://hubs.la/Q02MnjH_0 #iPSCs #cardiomyocytes #DrugDiscovery #StemCells #biopharma

Make sure you don't miss out on better in vitro models for human disease. Over the last decade, Axol have gained an international reputation for the production and characterization of functional, high quality iPSC-derived cells that are used to build human-relevant models for research and drug discovery. axoCells™ are used to explore: • Neuroscience: modeling neurodegenerative and neuroinflammatory diseases including ALS, Alzheimer’s disease and Huntington’s Disease • Pain and sensation: modeling pain and sensory function for drug discovery and neurotoxicity testing • Cardiovascular: using functional cardiomyocytes to model cardiac diseases (including arrhythmias) and for cardiotoxicity screening axoCells represent the leading edge of iPSC-derived cells models for neuroscience, pain and touch and cardiovascular disease. They are available direct from Axol, or from our trusted network of local distributors: • Lubio Science (Switzerland): https://hubs.la/Q02Mlh-20 • Cambridge Bioscience (UK and Ireland): https://hubs.la/Q02Ml7_j0 • MineBio (China): https://hubs.la/Q02MlgYJ0 • BioCat (Germany and Austria): https://hubs.la/Q02Ml9B90 • BioNordika (Norway, Finland, Iceland, Denmark, Sweden, Estonia, Latvia, Lithuania): https://hubs.la/Q02MlgZw0 or https://hubs.la/Q02Ml8Lc0 • Bio-connect (The Netherlands): https://hubs.la/Q02Ml8Lc0 Click here to see the full list: https://hubs.la/Q02MlgYG0 #iPSCs #MPS #Cardiotoxicity #Neuroscience #DrugDiscovery #StemCells

As MPS become more complex, it's essential to incorporate standardization. As it's not possible to standardize the different platforms themselves, standardization should focus on the cells and reagents used. At Axol Bioscience, we have developed a strategic approach to measuring cell performance across cell culture platforms or MPS devices, and a potential model for measurable criteria associated with neuronal cells and the platform, to validate batches of cells. Click here to download our poster where we demonstrate the use of multiple MPS platforms with human iPSC-derived neuronal cell types to build models of neurodegenerative disease and pain, and detail our approach to measuring cell performance across different cell culture platforms or MPS devices. https://hubs.la/Q02Mk_-90 Looking to get your platform "powered by axoCells™"? Get in contact at operations@axolbio.com #iPSCs #MPS #MicrophysiologicalSystems #microfluidics #StemCells

Our poll results are in! The Society for Neuroscience meeting in Chicago is the neuroscience conference people are most likely to attend this year. This is great news, as we will also be there, meeting up with existing partners and initiating new relationships with future collaborators and clients. We're looking forward to hearing about new developments in neuroscience, and hearing about the challenges of developing models for neuroscience research and drug discovery. As leading suppliers of high-quality human iPSCs, we’re helping to build more relevant in vitro models for neurodegenerative disease research and drug screening and we offer a catalog of high-quality neurons and neuroinflammatory cells: https://lnkd.in/epUnnZWt We look forward to seeing you there, but if you want to get in touch beforehand to discuss how we can help with your research, don't hesitate to drop us a line at operations@axolbio.com #neuroscience #iPSC #neurons #AlziemersDisease #StemCells

Looking to build in vitro cardiotoxicity and cardiac models to assess drug safety or for cardiac research? Let's have a conversation! Ventricular cardiomyocytes represent those found in the ventricles of the human heart. They are frequently used to fuel in vitro cardiotoxicity models to assess drug safety and for cardiac research, and can be used in co-culture with other cells, including atrial cardiomyocytes. Historically, a range of cardiotoxicity models have been used, including ex vivo and in vivo (animal) models, primary cell models (using cells taken directly from humans or animals), and in vitro immortalized cells expressing certain ion channels critical for cardiac function. In recent years, the industry has turned to more human-relevant model systems powered by human iPSC-derived cells to bridge the translational gap from bench to bedside that has hindered drug discovery and toxicology. axoCells™ human iPSC-derived ventricular cardiomyocytes can power advanced in vitro platforms for models investigating. Key highlights include: • Spontaneously beat 3 days post-thaw and are assay-ready in just 7 days • Validated against all 28 CiPA compounds • Demonstrate functional responses in a range of assay formats including patch clamp, electrophysiology and voltage-sensitive dyes • Manufactured in our ISO 9001-accredited production facility with excellent ISSCR Standards compliance Click here to read about the CiPA validation of our axoCells ventricular cardiomyocytes. In this application note we show that axoCells ventricular cardiomyocytes have applications for in vitro cardiac safety testing and detection of pro-arrhythmic risk of new compounds. https://hubs.la/Q02M9Vvh0 With a full complement of offerings and decades of in-house expertise, get in contact and see why we've become the first choice for cardiac researchers looking to use iPSC technology. Email us at operations@axolbio.com and let us know what we can do to help! #iPSCs #cardiotoxicity #StemCells #MPS #VentriclularCardiomyocytes

The organ-on-chip market is experiencing unprecedented growth, with the technology shaping the future of drug development and healthcare research. It's clear that OoC is no longer just a concept, but a transformative tool for the biomedical and pharmaceutical industries. OoC platforms allow for more accurate modelling of human physiology, driving breakthroughs in drug development and screening, disease modelling and personalized medicine. For those of us in the industry it's a really exciting time, and we are looking forward to continued advancements in the field. To find out how Axol can power your OoC research, get in touch at operations@axolbio.com Click here to read about our collaboration agreement with NETRI to power their organ-on-chip platforms with our axoCells iPSC-derived sensory neurons, alongside a joint R&D framework. https://lnkd.in/eaNyfCaR #OrganOnChip #iPSC #MPS #StemCells

Join innoVitro's webinar on September 19 at 4 PM CEST (10 AM ET, 7 AM PDT) to hear our Scientific Group Leader, Jamie Bhagwan, present findings on the differential contractility responses of axoCells™ hiPSC-derived atrial and ventricular cardiomyocytes when exposed to GPCR and ion channel modulating compounds. Register here: https://lnkd.in/eg4x5B-w #iPSCs #cardiomyocytes #webinar

It's great to see Axol's products being used in high quality translational research. Hot off the press is another new paper that our team have been involved in, "Activation of IP3R in atrial cardiomyocytes leads to generation of cytosolic cAMP" (Akerman et al, 2024) Excessive stimulation of the IP3-signalling pathway has been linked to atrial fibrillation (AF) through abnormal calcium handling. However, little is known about the mechanisms involved in this process. As part of the study, axoCells™ human iPSC-derived atrial cardiomyocytes were cultured on a microelectrode array (MEA) and Field Action Potentials (FAP) and contractility were recorded while the α-AR agonist, PE was added to the culture at increasing concentrations. The researchers found that indirect activation of the IP3 pathway in atrial myocytes using an alpha adrenergic receptor (α-AR) agonist phenylephrine (PE), and direct activation using IP3-AM, leads to an increase in cAMP and that these changes can be pharmacologically inhibited using IP3R inhibitors. axoCells atrial cardiomyocytes represent a highly validated, physiologically relevant model and have been extensively characterized structurally, functionally and morphologically. Protein and gene expression, beat rate and action potential parameters, along with functionality of the core cardiac and atrial-specific ion channels have been reported. The full paper can be found here: https://hubs.ly/Q02M1bvY0 To find out how iPSC-derived cardiomyocytes can help your studies, contact us at operations@axolbio.com #iPSCs #cardiomyoctes #DrugDiscovery #StemCells #biopharma #MicroelectrodeArray

#TechTuesday We're only too please to help. At Axol, we've spent more than a decade at the forefront of iPSC technology, adding to our bank of expertise in using iPSC-derived cells for drug discovery and research. Jessica Tilman PhD., took time out from her busy role as Scientific Group Leader at Axol, to speak with us about frequently asked questions for neurological immune cells. Jess is deeply involved in both microglia based product development and the delivery of service projects. She works in the cellular science group, and regularly participates in custom service projects, testing compounds on healthy and disease lines for disease specific phenotypes. Read the full interview here: https://hubs.la/Q02LKFXd0 If you are interested in using human iPSC-derived cells in your work, contact us at operation@axolbio.com. #TechTuesday #iPSCs #StemCells #Microglia